Key Highlights

  • Third quarter loss per share was USD 0.50, narrower than the estimated USD 0.56 loss, with no Revenue reported.
  • Cash and marketable securities were USD 798.4 million at September 30, 2026, against nine-month net loss of USD 71.7 million.
  • Phase 3 Study 304 in men showed hair count gains of 28.6 and 36.4 hairs per square centimeter.
  • Topline data from registration-directed Phase 2/3 Study 306 in women are guided for the first half of 2027.

Veradermics (NYSE:MANE), a clinical-stage company focused on pattern hair loss, reported a third quarter 2026 loss of USD 0.50 per share, narrower than the USD 0.56 estimated loss. The company reported no revenue. Net loss for the nine months was USD 71.7 million, up from USD 48.1 million a year earlier, and the accumulated Deficit was USD 195.2 million.

General and administrative expenses were USD 12.7 million in the quarter, against USD 2.3 million in the third quarter of 2025. Cash, cash equivalents and marketable securities were USD 798.4 million at September 30.

Phase 3 Data in Men

In October 2026 the company announced topline data from its Phase 3 trial, Study 304, which evaluated VDPHL01 in men with mild-to-moderate pattern hair loss. The study randomized 536 patients to 8.5 mg once daily, 8.5 mg twice daily or placebo. Patients achieved an average increase in non-vellus target area hair count of 28.6 hairs per square centimeter on once-daily dosing and 36.4 on twice-daily dosing, both with p-values below 0.0001. Patients on placebo showed an increase of 6.6 hairs per square centimeter from baseline.

The most common treatment-emergent adverse events occurring in more than 5% of patients versus placebo included peripheral edema and hypertrichosis.

In July 2026 the company announced topline results from Study 207, a Phase 2 open-label study in 21 men and 28 women. Among women who received 4.5 mg once or twice daily for six months, VDPHL01 showed what the company described as a potentially differentiated clinical profile, with rapid onset of activity, consistent response and increases in hair count. The company reported no treatment-related serious adverse events and no adverse events of special interest of cardiac origin. The most common adverse events were hypertrichosis and peripheral edema.

Enrollment is complete in the registration-directed Phase 2/3 trial, Study 306, in women with mild-to-moderate pattern hair loss. Topline data are guided for the first half of 2027. The company states its initial focus is pattern hair loss, which it says affects approximately 50 million men and 30 million women in the United States.

Financial Position and Reporting Notes

Net losses since inception are recurring, and the filing states management evaluated Going Concern conditions under the applicable accounting standard. With USD 798.4 million in cash and marketable securities, spending of USD 71.7 million over nine months is a small fraction of the balance.

The company's pre-funded warrants were exercised in August 2026, with investors buying 300,000 shares at an exercise price of USD 0.00001 per share.

What to Watch

The items to follow are the Study 306 readout in the first half of 2027, any regulatory filing plans for VDPHL01, and the change in general and administrative spending as the company scales. Safety observations such as peripheral edema remain part of how the data are read.